Build status - In Progress
Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy
Recruiting
19 years - 99 years
All
Phase
3
20 participants needed
1 Location
Brief description of study
The purpose of this study is to compare the effects of the study drug versus a placebo on reducing the number of septal reduction therapy procedures performed in patients with symptomatic oHCM.
Detailed description of study
The purpose of this study is to compare the effects of the study drug versus a placebo on reducing the number of septal reduction therapy procedures performed in patients with symptomatic oHCM.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Symptomatic Obstructive Hypertrophic Cardiomyopathy, Septal Reduction Therapy
-
Age: 19 years - 99 years
-
Gender: All
Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy
Updated on
04 Aug 2024.
Study ID: 842832
Find a site
,
Your Information has been sent successfully.
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study
Select a study center that’s convenient for you, and get in touch with the study team.
Contact a study centerPlease choose between Voice or SMS based delivery of verification code
or